Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
Study Details
Study Description
Brief Summary
This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients with Prolaris low-risk scores without negatively impacting patient oncologic outcomes, thereby sparing low-risk patients from unnecessary treatments and associated side-effects.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
This is a long-term prospective registry to evaluate the impact of Prolaris testing on therapeutic decisions in patients with newly diagnosed favorable intermediate-risk localized prostate cancer and to summarize clinical oncologic outcomes. The design of the study is non-interventional, and therefore the protocol will not require a specific treatment plan for study participants. However, in the absence of a universally accepted timeframe for repeat biopsies within existing active surveillance recommendations, study sites will be encouraged to monitor patients for disease progression as per the standard of care (e.g., current National Comprehensive Cancer Network [NCCN] guidelines) with the expectation of a repeat biopsy within 18 months of the initial biopsy.
Patients who undergo Prolaris testing will be included in the registry as well as patients who do not undergo Prolaris testing. Data collection for the first primary objective extends over a 3-year period. During this time, data is collected on the treatment initiated, any follow-up prostate biopsy performed in patients initially treated with active surveillance, definitive treatments performed (with pathology data if surgical therapy is performed), and the reasons definitive treatment was pursued, as well as data related to disease progression such as biochemical recurrence, development of prostate cancer metastases, or disease specific death.
Data collection for the second primary objective extends out to 8 years. During this time data is collected on any follow-up prostate biopsy in patients still treated with active surveillance, definitive treatments performed (with pathology data if surgical therapy is performed), and the reasons definitive treatment was pursued, as well as data related to disease progression such as biochemical recurrence, development of prostate cancer metastases, or disease specific death.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Prolaris Testing Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing |
Diagnostic Test: Prolaris Testing
Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
Other Names:
|
No Prolaris Testing Patients with newly diagnosed favorable intermediate-risk localized prostate cancer who DO NOT undergo Prolaris testing |
Outcome Measures
Primary Outcome Measures
- Low Prolaris Score, on Active Surveillance [3 years]
Proportion of patients with low Prolaris scores who are initially treated with active surveillance
- Low Prolaris Score, Definitive Treatment Following Active Surveillance [3 years]
Proportion of patients with low Prolaris scores and initially treated with active surveillance who proceed to definitive treatment at 3 year follow-up
- Low Prolaris Score, Disease Progression Following Delayed Definitive Treatment [8 years]
Proportion of patients with low Prolaris scores and initially treated with active surveillance and later proceed to definitive treatment who develop disease progression at 5 years subsequent to the start of definitive treatment.
Secondary Outcome Measures
- Low Prolaris Score, Time to Definitive Treatment following Active Surveillance [8 years]
Time to definitive treatment in patients with low Prolaris scores who are initially treated with active surveillance.
- No Prolaris Score, on Active Surveillance [3 years]
Proportion of patients without Prolaris testing who are initially treated with active surveillance.
- No Prolaris Score, Definitive Treatment Following Active Surveillance [3 years]
Proportion of patients without Prolaris testing initially treated with active surveillance who proceed to definitive treatment at 3 year follow-up.
- No Prolaris Score, Time to Definitive Treatment Following Active Surveillance [8 years]
Time to definitive treatment in patients without Prolaris testing who are initially treated with Active Surveillance.
- No Prolaris Score, Disease Progression Following Delayed Definitive Treatment [8 years]
Proportion of patients without Prolaris testing and initially treated with active surveillance who proceed with definitive treatment that develop disease progression at 5 years subsequent to the start of definitive treatment.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients who have undergone CCP testing and patients who have not undergone CCP testing will be considered for enrollment in the study.
-
Willing to provide written informed consent.
-
Males ≥65 years old.
-
Newly diagnosed (≤6 months), treatment-naïve patient with histologically proven localized adenocarcinoma of prostate whose initial treatment has not been decided.
-
Candidate for and considering AS and yet would be eligible for definitive therapy.
-
Favorable intermediate-risk disease, defined by the NCCN as follows:
-
predominant Gleason grade 3; AND
-
percentage of positive cores <50%; AND
-
no more than 1 of the following NCCN intermediate-risk factors:
-
Gleason grade 7
-
T2b-T2c
-
PSA 10-20 ng/mL
-
Estimated life expectancy ≥10 years.
-
Can be monitored for disease progression according to standard of care (e.g., current NCCN guidelines).
Exclusion Criteria:
-
- Clinical evidence of metastasis or lymph node involvement.
-
- Received pelvic radiation prior to biopsy.
-
- Received androgen deprivation therapy (ADT) prior to biopsy; however, 5 alpha-reductase inhibitors (5-ARIs) are permitted.
-
- Participation in interventional clinical trials.
-
- Patient is considering watchful waiting.
-
- Has a known history of hypogonadism.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Urology Centers of Alabama | Homewood | Alabama | United States | 35209 |
2 | East Valley Urology Center | Mesa | Arizona | United States | 85206 |
3 | University of Arkansas for Medical Sciences | Little Rock | Arkansas | United States | 72205 |
4 | Arkansas Urology | Little Rock | Arkansas | United States | 72211 |
5 | Pacific Urology | Concord | California | United States | 94520 |
6 | VA Long Beach Healthcare | Long Beach | California | United States | 90822 |
7 | UCI Medical Center | Orange | California | United States | 92866 |
8 | Ssg Md Apc | San Jose | California | United States | 95124 |
9 | Advanced Urology Institute | Daytona Beach | Florida | United States | 32114 |
10 | Urology Group of Florida | Delray Beach | Florida | United States | 33484 |
11 | Pinellas Urology | Saint Petersburg | Florida | United States | 33710 |
12 | 21st Century Oncology | Sunrise | Florida | United States | 33351 |
13 | Meridian Clinical Research | Savannah | Georgia | United States | 31405 |
14 | North Idaho Urology | Coeur d'Alene | Idaho | United States | 83814 |
15 | URO Partners | Westchester | Illinois | United States | 60154 |
16 | Wichita Urology | Wichita | Kansas | United States | 67226 |
17 | Regional Urology | Shreveport | Louisiana | United States | 71106 |
18 | Tufts Medical Center | Boston | Massachusetts | United States | 02111 |
19 | University of Michigan, Department of Urologic Oncology | Ann Arbor | Michigan | United States | 48109 |
20 | Comprehensive Urology | Royal Oak | Michigan | United States | 48073 |
21 | Michigan Institute of Urology | Troy | Michigan | United States | 48084 |
22 | UroLogic | Tupelo | Mississippi | United States | 38801 |
23 | Premier Urology Group, LLC | Cranford | New Jersey | United States | 07016 |
24 | Premier Urology | Cranford | New Jersey | United States | 07016 |
25 | Urologic Research and Consulting LLC | Englewood | New Jersey | United States | 07631 |
26 | Stony Brook University | Stony Brook | New York | United States | 11794 |
27 | A.M.P. Radiation Oncology | Syracuse | New York | United States | 13210 |
28 | Associated Urologists of North Carolina | Raleigh | North Carolina | United States | 27612 |
29 | Lehigh Valley Health Network | Allentown | Pennsylvania | United States | 18103 |
30 | Medical University of South Carolina | Charleston | South Carolina | United States | 29425 |
31 | Carolina Urology Partners | West Columbia | South Carolina | United States | 29163 |
32 | Urology Associates | Nashville | Tennessee | United States | 37209 |
33 | Rio Grande Urology | El Paso | Texas | United States | 79912 |
34 | Seattle Urology Research Center | Burien | Washington | United States | 98166 |
Sponsors and Collaborators
- Myriad Genetic Laboratories, Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- URO-008